↓ Skip to main content

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol

Overview of attention for article published in BMC Cancer, December 2014
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (54th percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

wikipedia
1 Wikipedia page

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
55 Mendeley
citeulike
2 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol
Published in
BMC Cancer, December 2014
DOI 10.1186/1471-2407-14-983
Pubmed ID
Authors

Shibani Nicum, Corran Roberts, Lucy Boyle, Sylwia Kopijasz, Charlie Gourley, Marcia Hall, Ana Montes, Christopher Poole, Linda Collins, Anna Schuh, Susan J Dutton

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 55 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 20%
Student > Bachelor 11 20%
Student > Ph. D. Student 5 9%
Student > Master 5 9%
Lecturer 2 4%
Other 6 11%
Unknown 15 27%
Readers by discipline Count As %
Medicine and Dentistry 15 27%
Pharmacology, Toxicology and Pharmaceutical Science 7 13%
Biochemistry, Genetics and Molecular Biology 5 9%
Nursing and Health Professions 3 5%
Psychology 3 5%
Other 6 11%
Unknown 16 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2019.
All research outputs
#7,478,082
of 22,860,626 outputs
Outputs from BMC Cancer
#2,068
of 8,319 outputs
Outputs of similar age
#105,575
of 353,462 outputs
Outputs of similar age from BMC Cancer
#45
of 157 outputs
Altmetric has tracked 22,860,626 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,319 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,462 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 157 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.